Title |
The impact of Medicare prescription drug coverage on the use of antidementia drugs
|
---|---|
Published in |
BMC Geriatrics, April 2013
|
DOI | 10.1186/1471-2318-13-37 |
Pubmed ID | |
Authors |
Nicole R Fowler, Yi-Fan Chen, Christiana A Thurton, Aiju Men, Eric G Rodriguez, Julie M Donohue |
Abstract |
Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although the efficacy of these drugs has been demonstrated, their effectiveness, from the perspective of patients and caregivers, has been questioned. Little is known about whether the demand for cholinesterase inhibitors and memantine are sensitive to out-of-pocket cost. Using the 2006 implementation of Medicare Part D as a natural experiment, this study examines the impact of changes in drug coverage on use of cholinesterase inhibitors and memantine by comparing use before and after Medicare Part D implementation among older adults who did and did not experience a change in coverage. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 17% |
Unknown | 5 | 83% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 3% |
Unknown | 39 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 13% |
Student > Bachelor | 4 | 10% |
Student > Doctoral Student | 4 | 10% |
Lecturer | 3 | 8% |
Other | 3 | 8% |
Other | 8 | 20% |
Unknown | 13 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Psychology | 3 | 8% |
Nursing and Health Professions | 3 | 8% |
Social Sciences | 3 | 8% |
Other | 6 | 15% |
Unknown | 16 | 40% |